Bromodeoxyuridine uptake and proliferating cell nuclear antigen expression throughout the colorectal tumor sequence

Area of Science:

• Gastroenterology
• Oncology
• Cell Biology

Background:

• Colorectal neoplasia involves altered cell proliferation.
• Bromodeoxyuridine (BrdU) and proliferating cell nuclear antigen (PCNA) are markers of cell proliferation.
• Understanding proliferation dynamics is crucial for assessing tumor progression risk.

Purpose of the Study:

• To compare in vitro bromodeoxyuridine uptake and PCNA expression in rectal mucosa.
• To evaluate these markers in relation to colorectal tumor progression (adenomas and adenocarcinomas).
• To determine if PCNA is a sensitive indicator of tumor transformation risk.

Main Methods:

• Histochemical analysis of rectal mucosa from control subjects and patients with colorectal neoplasia.
• In vitro uptake of bromodeoxyuridine (BrdU) to assess DNA synthesis.
• Immunohistochemical detection of proliferating cell nuclear antigen (PCNA) expression.
• Correlation analysis of BrdU and PCNA labeling indices across different stages of neoplasia.

Main Results:

• Both BrdU and PCNA labeling indices increased with tumor progression.
• PCNA labeling indices were consistently higher than BrdU indices.
• Correlation between BrdU and PCNA weakened significantly in high-grade dysplasia and adenocarcinomas.
• PCNA indicated hyperproliferation but not the specific proliferative compartment shift seen with BrdU.

Conclusions:

• Increased PCNA expression in colorectal neoplasia reflects both hyperproliferation and deregulation of PCNA synthesis.
• PCNA alone is insufficient to detect the surface-ward shift of the proliferative compartment.
• PCNA expression is not a sufficiently sensitive marker for predicting tumor transformation risk in intestinal mucosa.